Email  |  BV_FTP  |  OA

Hotline:+86 27 8798 8585  CN   |   EN

CN   |   EN

Current location:Home >> Latest News >> Company News

BravoVax CEO was Invited to Attend “VacFuture 2022-RNA Therapeutics & Novel Vaccine Industry Summit"

Author:博沃管理员    Release time:2022-08-18 16:30:00

On August 16-17th, 2022, ”VacFuture 2022-RNA Therapeutics & Novel Vaccine Industry Summit" was held in Guangzhou, China. BravoBio was invited to the Summit.

8-18-01.png

With the theme of “Breakthroughs in RNA Therapeutics; drawing a blueprint for China-made next-generation vaccines”, KOLs from bio-industries gathered in the Summit, and shared their viewpoints and perspectives on the new trend of development of RNA therapeutics and novel vaccines. The Summit was divided into 2 venues — “Innovative RNA Therapeutics Forum” and “Novel Vaccine Industry Forum”. Dr. Wu Ke, Founder & CEO of BravoBio, was invited and gave a keynote speech on “Perspectives on the development trend of next-generation vaccines”.

8-18-02.png
8-18-03.png

Dr. Wu said, with the endless variation of coronavirus, there is a high demand for innovative ideas for vaccine development if we want to go back to normal life. He pointed out, the development trend of next-generation vaccines will be vaccines that can induce mucosal immunity and broad-spectrum vaccines. It is required for the companies to adopt differentiation strategies and to develop vaccines that can provide a higher, more robust, and more consistent level of immunity.


BravoBio has been dedicated in human vaccines for many years, and especially focused on vaccine innovation. Since long ago, BravoBio has prospectively and strategically included the mucosal vaccines and broad-spectrum vaccines into its pipeline. We are hoping these products will be launched in the market as soon as possible, to fill the gap in the market and promote the development of vaccine industry.